Intas Biopharmaceuticals is launching lung cancer drug Gefitinib in India and will sell it under ‘Geffy’ brand name.

Smoking, occupational exposure to carcinogens indoor air pollution and dietary factors have been major causes of lung cancer. In view of large population, the burden of lung cancer will be enormous in India.

As per recent studies and estimates, more than 90,000 men and 79,000 women are diagnosed each year with cancer of the lungs and bronchi (the air tubes leading to the lungs). Among men, the incidence of lung cancer has been declining, but it continues to increase among women. The number of lung cancer deaths among women surpasses those from breast cancer. Female smokers may be more likely to develop lung cancer than male smokers.

Intas Biopharmaceuticals has launched Geffy for treatment of lung cancer especially non-small cell lung cancer (NSCLC). Geffy is a class of anti-cancer medications called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.

Intas Biopharmaceuticals is focusing on marketing novel therapies and drugs that cater to Solid Tumors, Hematology and Supportive Therapies. Expanding its current portfolio of lung cancer drugs, which comprises of Gemibine, Carbopa, Taxocare and Cytax, Intas is eying to grab a major market share in India.

Simon Daniel, Chief Executive, Marketing, Intas Biopharmaceuticals said that the introduction of Geffy in the company’s product basket is going to strengthen the domestic market share for the lung cancer market.